Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines

Authors: Li-Hsuen Chen, Wen-Lin Hsu, Yen-Ju Tseng, Dai-Wei Liu, Ching-Feng Weng

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

The 5-year overall survival rates for head and neck cancer (HNC) relies on distant metastasis. Importantly, the epithelial-mesenchymal transition (EMT) is believed to be an initial step of metastasis. However, the relationship of epigenetic with EMT formation is still unexplored in HNC. This study focuses on invasive subclones of HNC cell lines through the simulation of invasion in vitro; and underlying mechanisms were analyzed including DNA methylation and gene expression profile.

Methods

Invasive subclones of NHC cell lines were successfully obtained using transwell coated with Matrixgel. Cells invaded through 8 μm pore several times were subcultured and examined with EMT features including morphology, EMT marker genes expression, and invasive ability. Moreover, compared the profile of genes expression in parental and invasive cells was analyzed using mRNA expression array.

Results

DNA methyltransferase 3B (DNMT 3B) was upregulated in invasive subclones and might control the 5′ region of E-cadherin (E-cad) methylation and further inhibited E-cad protein expression. Interference of DNMT 3B by siRNA or miRNA 29b could reduce EMT and cell invasion. Expression array analysis revealed the most possible involved pathways in cell invasion including arginine and proline metabolism, TGF-beta, and focal adhesion.

Conclusions

DNMT 3B might control EMT by DNA methylation manner in invasive HNC cell lines. Moreover, miR-29b mimic downregulated DNMT 3B and inhibited EMT and cell invasion indicated the role of therapeutic agent for invasive HNC. Genes identified from array data and new molecules are involved in metastasis of HNC need further validation.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.CrossRefPubMed
2.
Freedman N, Schatzkin A, Leitzmann M, Hollenbeck A, Abnet C. Alcohol and head and neck cancer risk in a prospective study. Br J Cancer. 2007;96(9):1469–74.PubMedPubMedCentral
3.
Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels AB, Maisonneuve P, Boyle P. Tobacco smoking and cancer: A meta‐analysis. Int J Cancer. 2008;122(1):155–64.CrossRefPubMed
4.
Hashibe M, Brennan P, Benhamou S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Wünsch-Filho V. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst. 2007;99(10):777–89.CrossRefPubMed
5.
Humans IWGotEoCRt, Organization WH, Cancer IAfRo. Betel-quid and areca-nut chewing and some areca-nut-derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum. 2004;85:1–334.
6.
Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, Rajkumar T, Sridhar H, Rose B, Pintos J. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772–83.CrossRefPubMed
7.
Leemans CR, Tiwari R, Nauta J, Van der Waal I, Snow GB. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993;71(2):452–6.CrossRefPubMed
8.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011;11(1):9–22.CrossRefPubMed
9.
Chambers AF, Groom AC, MacDonald IC. Metastasis: dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2(8):563–72.CrossRefPubMed
10.
Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796(2):293–308.PubMed
11.
Thiery JP. Epithelial–mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15(6):740–6.CrossRefPubMed
12.
13.
Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442–54.CrossRefPubMed
14.
Tse JC, Kalluri R. Mechanisms of metastasis: epithelial‐to‐mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem. 2007;101(4):816–29.CrossRefPubMed
15.
16.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28(1–2):15–33.CrossRefPubMed
17.
Junghans D, Haas IG, Kemler R. Mammalian cadherins and protocadherins: about cell death, synapses and processing. Curr Opin Cell Biol. 2005;17(5):446–52.CrossRefPubMed
18.
Jechlinger M, Grunert S, Tamir IH, Janda E, Lüdemann S, Waerner T, Seither P, Weith A, Beug H, Kraut N. Expression profiling of epithelial plasticity in tumor progression. Oncogene. 2003;22(46):7155–69.CrossRefPubMed
19.
Lingen M, Pinto A, Mendes R, Franchini R, Czerninski R, Tilakaratne W, Partridge M, Peterson D, Woo SB. Genetics/epigenetics of oral premalignancy: current status and future research*. Oral Dis. 2011;17(s1):7–22.CrossRefPubMed
20.
Luczak MW, Jagodzinski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006;44(3):143–54.PubMed
21.
22.
Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247–57.CrossRefPubMed
23.
Chang HW, Chow V, Lam KY, Wei WI, Wing Yuen AP. Loss of E‐cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer. 2002;94(2):386–92.CrossRefPubMed
24.
Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol. 2006;7(1):77–82.CrossRefPubMed
25.
Chu YW, Yang PC, Yang SC, Shyu YC, Hendrix MJ, Wu R, Wu CW. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 1997;17(3):353–60.CrossRefPubMed
26.
Chang K-T, Tsai M-J, Cheng Y-T, Chen J-J, Hsia R-H, Lo Y-S, Ma Y-R, Weng C-F. Comparative atomic force and scanning electron microscopy: an investigation of structural differentiation of hepatic stellate cells. J Struct Biol. 2009;167(3):200–8.CrossRefPubMed
27.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93(18):9821–6.CrossRefPubMedPubMedCentral
28.
Chen L-H, Liu D-W, Chang J-L, Chen P-R, Hsu L-P, Lin H-Y, Chou Y-F, Lee C-F, Yang M-C, Wen Y-H. Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer. J Exp Clin Cancer Res. 2015;34(1):1.CrossRef
29.
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101–8.CrossRefPubMed
30.
Boyer B, Thiery JP. Epithelium‐mesenchyme interconversion as example of epithelial plasticity. APMIS. 1993;101(1–6):257–68.CrossRefPubMed
31.
Hay E. An overview of epithelio-mesenchymal transformation. Cells Tissues Organs. 1995;154(1):8–20.CrossRef
32.
Machesky LM. Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 2008;582(14):2102–11.CrossRefPubMed
33.
Ibarra N, Pollitt A, Insall R. Regulation of actin assembly by SCAR/WAVE proteins. Biochem Soc Trans. 2005;33(Pt 6):1243–6.CrossRefPubMed
34.
Innocenti M, Zucconi A, Disanza A, Frittoli E, Areces LB, Steffen A, Stradal TE, Di Fiore PP, Carlier M-F, Scita G. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat Cell Biol. 2004;6(4):319–27.CrossRefPubMed
35.
Kunda P, Craig G, Dominguez V, Baum B. Abi, Sra1, and Kette control the stability and localization of SCAR/WAVE to regulate the formation of actin-based protrusions. Curr Biol. 2003;13(21):1867–75.CrossRefPubMed
36.
Svitkina TM, Bulanova EA, Chaga OY, Vignjevic DM, Kojima S-I, Vasiliev JM, Borisy GG. Mechanism of filopodia initiation by reorganization of a dendritic network. J Cell Biol. 2003;160(3):409–21.CrossRefPubMedPubMedCentral
37.
Hashimoto Y, Parsons M, Adams JC. Dual actin-bundling and protein kinase C-binding activities of fascin regulate carcinoma cell migration downstream of Rac and contribute to metastasis. Mol Biol Cell. 2007;18(11):4591–602.CrossRefPubMedPubMedCentral
38.
39.
Roll JD, Rivenbark AG, Jones WD, Coleman WB. DNMT3b overexpression contributes to a hypermethylator phenotype in human breast cancer cell lines. Mol Cancer. 2008;7(1):15.CrossRefPubMedPubMedCentral
40.
Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri‐centromeric satellite regions in human colorectal and stomach cancers. Int J Cancer. 2001;91(2):205–12.CrossRefPubMed
41.
Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res. 2009;15(11):3663–71.CrossRefPubMedPubMedCentral
42.
Lin T-S, Lee H, Chen R-A, Ho M-L, Lin C-Y, Chen Y-H, Tsai YY, Chou M-C, Cheng Y-W. An association of DNMT3b protein expression with P16INK4a promoter hypermethylation in non-smoking female lung cancer with human papillomavirus infection. Cancer Lett. 2005;226(1):77–84.CrossRefPubMed
43.
Lin H, Yamada Y, Nguyen S, Linhart H, Jackson-Grusby L, Meissner A, Meletis K, Lo G, Jaenisch R. Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol Cell Biol. 2006;26(8):2976–83.CrossRefPubMedPubMedCentral
44.
Linhart HG, Lin H, Yamada Y, Moran E, Steine EJ, Gokhale S, Lo G, Cantu E, Ehrich M, He T. Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencing. Genes Dev. 2007;21(23):3110–22.CrossRefPubMedPubMedCentral
45.
Hameed R, Raimondi SL. The role of aberrant DNMT3Bs in tumor progression–a review. Cancer Cell Microenviron. 2015;2(2):e847. 10-14800/ccm. 14847.
46.
Ostler K, Davis E, Payne S, Gosalia B, Exposito-Cespedes J, Le Beau M, Godley L. Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene. 2007;26(38):5553–63.CrossRefPubMedPubMedCentral
47.
Brambert PR, Kelpsch DJ, Hameed R, Desai CV, Calafiore G, Godley LA, Raimondi SL. DNMT3B7 Expression Promotes Tumor Progression to a More Aggressive Phenotype in Breast Cancer Cells. PLoS ONE. 2015;10(1):e0117310.CrossRefPubMedPubMedCentral
48.
Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci. 2007;104(40):15805–10.CrossRefPubMedPubMedCentral
49.
Cortez MA, Nicoloso MS, Shimizu M, Rossi S, Gopisetty G, Molina JR, Carlotti C, Tirapelli D, Neder L, Brassesco MS. miR‐29b and miR‐125a regulate podoplanin and suppress invasion in glioblastoma. Genes Chromosom Cancer. 2010;49(11):981–90.CrossRefPubMed
50.
Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73.CrossRefPubMed
51.
Flavin R, Smyth P, Barrett C, Russell S, Wen H, Wei J, Laios A, O’Toole S, Ring M, Denning K. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009;19(4):641–7.CrossRefPubMed
52.
Kinoshita T, Nohata N, Hanazawa T, Kikkawa N, Yamamoto N, Yoshino H, Itesako T, Enokida H, Nakagawa M, Okamoto Y. Tumour-suppressive microRNA-29 s inhibit cancer cell migration and invasion by targeting laminin–integrin signalling in head and neck squamous cell carcinoma. Br J Cancer. 2013;109(10):2636–45.CrossRefPubMedPubMedCentral
53.
Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, Zhuang SM. Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology. 2010;51(3):836–45.PubMed
54.
55.
Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA. MicroRNA 29b functions in acute myeloid leukemia. Blood. 2009;114(26):5331–41.CrossRefPubMedPubMedCentral
56.
Rothschild SI, Tschan M, Federzoni E, Jaggi R, Fey M, Gugger M, Gautschi O. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene. 2012;31(38):4221–32.CrossRefPubMed
57.
Li H, Solomon E, Muggy SD, Sun D, Zolkiewska A. Metalloprotease-disintegrin ADAM12 expression is regulated by Notch signaling via microRNA-29. J Biol Chem. 2011;286(24):21500–10.CrossRefPubMedPubMedCentral
58.
Chou J, Lin JH, Brenot A, Kim J-W, Provot S, Werb Z. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013;15(2):201–13.CrossRefPubMedPubMedCentral
59.
Melo SA, Kalluri R. miR-29b moulds the tumour microenvironment to repress metastasis. Nat Cell Biol. 2013;15(2):139–40.CrossRefPubMed
60.
Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood. 2009;113(25):6411–8.CrossRefPubMedPubMedCentral
61.
62.
63.
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389(6648):300–5.CrossRefPubMed
64.
Liu Y, Borchert GL, Donald SP, Diwan BA, Anver M, Phang JM. Proline oxidase functions as a mitochondrial tumor suppressor in human cancers. Cancer Res. 2009;69(16):6414–22.CrossRefPubMedPubMedCentral
65.
Liu W, Zabirnyk O, Wang H, Shiao Y, Nickerson M, Khalil S, Anderson L, Perantoni A, Phang J. miR-23b* targets proline oxidase, a novel tumor suppressor protein in renal cancer. Oncogene. 2010;29(35):4914–24.CrossRefPubMedPubMedCentral
66.
67.
Moustakas A, Heldin CH. Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci. 2007;98(10):1512–20.CrossRefPubMed
68.
Zhang Y, Feng X-H, Wu R-Y, Derynck R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature. 1996;383:168–72.CrossRefPubMed
69.
Yang L, Mao C, Teng Y, Li W, Zhang J, Cheng X, Li X, Han X, Xia Z, Deng H. Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. Cancer Res. 2005;65(19):8671–8.CrossRefPubMed
70.
Qiao W, Li A, Owens P, Xu X, Wang X, Deng C. Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene. 2006;25(2):207–17.PubMed
71.
Bornstein S, White R, Malkoski S, Oka M, Han G, Cleaver T, Reh D, Andersen P, Gross N, Olson S. Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest. 2009;119(11):3408.PubMedPubMedCentral
72.
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ,Fakhry C, Xie T-X, Zhang J, Wang J. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–7.CrossRefPubMedPubMedCentral
73.
Kim SK, Fan Y, Papadimitrakopoulou V, Clayman G, Hittleman WN, Hong WK, Lotan R, Mao L. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res. 1996;56(11):2519–21.PubMed
74.
Cardenas H, Vieth E, Lee J, Segar M, Liu Y, Nephew KP, Matei D. TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics. 2014;9(11):1461–72.CrossRefPubMedPubMedCentral
75.
76.
Ozdamar B, Bose R, Barrios-Rodiles M, Wang H-R, Zhang Y, Wrana JL. Regulation of the polarity protein Par6 by TGFß receptors controls epithelial cell plasticity. Science. 2005;307(5715):1603–9.CrossRefPubMed
77.
Yamashita M, Fatyol K, Jin C, Wang X, Liu Z, Zhang YE. TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β. Mol Cell. 2008;31(6):918–24.CrossRefPubMedPubMedCentral
78.
79.
Grinnell F, Billingham RE, Burgess L. Distribution of fibronectin during wound healing in vivo. J Investig Dermatol. 1981;76(3):181–9.CrossRefPubMed
80.
Han S, Khuri FR, Roman J. Fibronectin stimulates non–small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66(1):315–23.CrossRefPubMed
81.
Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene. 2014;33(13):1649–57.CrossRefPubMed
82.
Chen S-Y, Lin J-S, Yang B-C. Modulation of tumor cell stiffness and migration by type IV collagen through direct activation of integrin signaling pathway. Arch Biochem Biophys. 2014;555:1–8.CrossRefPubMed
83.
Jinnin M, Ihn H, Asano Y, Yamane K, Trojanowska M, Tamaki K. Tenascin-C upregulation by transforming growth factor-β in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene. 2004;23(9):1656–67.CrossRefPubMed
84.
Jahkola T, Toivonen T, Virtanen I, von Smitten K, Nordling S, von Boguslawski K, Haglund C, Nevanlinna H, Blomqvist C. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998;78(11):1507.CrossRefPubMedPubMedCentral
85.
Orend G, Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett. 2006;244(2):143–63.CrossRefPubMed
86.
De Wever O, Nguyen Q-D, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, Mareel M. Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J. 2004;18(9):1016–8.PubMed
87.
Dandachi N, Hauser‐Kronberger C, More E, Wiesener B, Hacker G, Dietze O, Wirl G. Co‐expression of tenascin‐C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol. 2001;193(2):181–9.CrossRefPubMed
Metadata
Title
Involvement of DNMT 3B promotes epithelial-mesenchymal transition and gene expression profile of invasive head and neck squamous cell carcinomas cell lines
Authors
Li-Hsuen Chen
Wen-Lin Hsu
Yen-Ju Tseng
Dai-Wei Liu
Ching-Feng Weng
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2468-x

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

At least two well-spaced samples are needed to genotype a solid tumor

Study protocol

The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress

Research article

Basal metabolic state governs AIF-dependent growth support in pancreatic cancer cells

Study protocol

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours

Research article

The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients

Research article

Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits